JAMA Cardiology
Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study
June 23, 2016Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research
A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …
